Once the initial renal cell carcinoma (RCC) starts to spread, it becomes advanced RCC.1,2
To treat advanced RCC, guidelines recommend a number of treatments belonging to one of two drug classes: Targeted therapies or immunotherapies.1,2
Treatments for advanced RCC
|Drugs (generic name)|
|Targeted therapies||Inlyta (axitinib)
|Immunotherapies||High-dose IL-2||Opdivo (nivolumab)|
|Combination therapies||Avastin + interferon-α2a||Lenvima + Afinitor|
Generally, internationally recognized guidelines recommend:
- Surgery to remove as much tumour tissue as possible.1,2
- If RCC relapses or if not all tumours can be removed, start on an appropriate targeted therapy, combination therapy, or high-dose IL-2.1,2
- Should the first-line treatment fail, options are to enroll in a clinical trial, or treat with another targeted therapy, immunotherapy, or combination therapy.1,2
Treatments are often chosen based on the patient’s risk of progression.
To learn more:
References: 1. National Comprehensive Cancer Network. NCCN guidelines: Kidney cancer version 3.2016. Available at: https://www.nccn.org. Accessed on August 11, 2016. 2. Escudier B, et al. Ann Oncol 2014;25(Suppl 3):iii49-iii56.